Departments of Anesthesiology (D.J.S., A.L.G., J.H.S., G.A.) and Developmental Biology (D.F.C.), and the Taylor Family Institute for Innovative Psychiatric Research (D.F.C., J.H.S., G.A.), Washington University School of Medicine, St. Louis, Missouri.
Departments of Anesthesiology (D.J.S., A.L.G., J.H.S., G.A.) and Developmental Biology (D.F.C.), and the Taylor Family Institute for Innovative Psychiatric Research (D.F.C., J.H.S., G.A.), Washington University School of Medicine, St. Louis, Missouri
Mol Pharmacol. 2019 Jan;95(1):70-81. doi: 10.1124/mol.118.113464. Epub 2018 Oct 18.
Under both physiologic and clinical conditions GABA receptors are exposed to multiple agonists, including the transmitter GABA, endogenous or exogenous neuroactive steroids, and various GABAergic anesthetic and sedative drugs. The functional output of the receptor reflects the interplay among all active agents. We have investigated the activation of the concatemeric 122L GABA receptor by combinations of agonists. Simulations of receptor activity using the coagonist concerted transition model demonstrate that the response amplitude in the presence of agonist combinations is highly dependent on whether the paired agonists interact with the same or distinct sites. The experimental data for receptor activation by agonist combinations were in agreement with the established views of the overlap of binding sites for several pairs of orthosteric (GABA, -alanine, and piperidine-4-sulfonic acid) and/or allosteric agents (propofol, pentobarbital, and several neuroactive steroids). Conversely, the degree of potentiation when two GABAergic agents are coapplied can be used to determine whether the compounds act by binding to the same or distinct sites. We show that common interaction sites mediate the actions of 5- and 5-reduced neuroactive steroids, and natural and enantiomeric steroids. Furthermore, the results indicate that the anesthetics propofol and pentobarbital interact with partially shared binding sites. We propose that the findings may be used to predict the efficacy of drug mixtures in combination therapy and thus have potential clinical relevance.
在生理和临床条件下,GABA 受体暴露于多种激动剂,包括递质 GABA、内源性或外源性神经活性甾体和各种 GABA 能麻醉和镇静药物。受体的功能输出反映了所有活性物质的相互作用。我们研究了串联 122L GABA 受体与激动剂组合的激活。使用共激动剂协同转变模型模拟受体活性表明,在存在激动剂组合的情况下,响应幅度高度依赖于配对激动剂是否与相同或不同的位点相互作用。激动剂组合激活受体的实验数据与几个对映体(GABA、-丙氨酸和哌啶-4-磺酸)和/或变构剂(异丙酚、戊巴比妥和几种神经活性甾体)的结合位点重叠的既定观点一致。相反,当两种 GABA 能药物同时应用时的增效程度可用于确定化合物是否通过与相同或不同的位点结合而发挥作用。我们表明,常见的相互作用位点介导 5-和 5-还原的神经活性甾体以及天然和对映体甾体的作用。此外,结果表明麻醉剂异丙酚和戊巴比妥与部分共享的结合位点相互作用。我们提出,这些发现可用于预测药物混合物联合治疗的疗效,因此具有潜在的临床相关性。